Stock Watch: Regeneron’s Constellation of Ophthalmic Competition
When One Product Loses Exclusivity, Potentially All Market Shares Can Suffer
The accepted commercial dynamics of a competitive indication in older patients can be disrupted by new entrants with improved profiles, lower priced biosimilar competition and (soon) Medicare price negotiations.
You may also be interested in...
Rarely does the best-selling product emerge when a newer antibody platform is used to improve on a successful earlier-generation product. Better to play to the platform’s strengths.
While the implications of the US Inflation Reduction Act are the focus of the sector’s concern this year, another regulatory development will impact earnings sooner.
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.